Eccrine Carcinoma Follow-up

  • Author: Anthony Wong, MD, FAAD; Chief Editor: Dirk M Elston, MD   more...
 
Updated: Mar 26, 2010
 

Deterrence/Prevention

  • Sun protection would be prudent to the extent that UVR is considered a potential causative factor in eccrine carcinoma; however, this is only speculative at this point.
Next

Complications

  • Eccrine carcinomas may cause complications secondary to local invasion or metastatic disease.
Previous
Next

Prognosis

  • After studying a group of 35 patients with a limited variety of eccrine carcinoma subtypes, Mehregan et al[17] concluded that while all have a tendency for local recurrence, local lymphatic spread or distant metastasis occurs in less than 10% of cases. Indeed, the precise behavior of a given tumor seems to correlate well with its histologic subtype. While the prognosis for disseminated disease is believed to be grim, insufficient experience exists to allow tabulation of specific survival data.
    • Sclerosing sweat duct carcinoma and primary cutaneous adenoid cystic carcinoma have been implicated in local recurrences only.[18]
    • Eccrine adenocarcinoma, malignant chondroid syringoma, and malignant nodular hidradenoma are particularly prone to metastasize.[19]
    • Porocarcinoma also may metastasize widely.
    • Malignant eccrine spiradenoma reportedly spreads to regional lymph nodes and systemically, but too few cases have been described to enable a generalized statement regarding the behavior of this tumor.
    • Mucinous eccrine carcinoma occasionally spreads to regional nodes but only rarely metastasizes.
    • Aggressive digital papillary tumors are locally destructive but also metastasize not infrequently (14% in one study).[20]
Previous
 
Contributor Information and Disclosures
Author

Anthony Wong, MD, FAAD  Consulting Staff, Department of Dermatology, SUNY Health Science Center at Brooklyn, St Catherine's of Sienna, and Long Island Skin Cancer and Dermatologic Surgery, PC

Anthony Wong, MD, FAAD is a member of the following medical societies: American Academy of Dermatology and American College of Mohs Micrographic Surgery and Cutaneous Oncology

Disclosure: Nothing to disclose.

Coauthor(s)

Darren Keith Mollick, MD  Clinical Assistant Professor, Department of Dermatology, State University of New York Downstate Medical Center

Disclosure: Nothing to disclose.

Daniel Mark Siegel, MD, MS  Director, Procedural Dermatology Fellowship Program, Clinical Professor of Dermatology, Department of Dermatology, State University of New York Downstate

Daniel Mark Siegel, MD, MS is a member of the following medical societies: American Academy of Dermatology, American College of Mohs Micrographic Surgery and Cutaneous Oncology, American College of Physician Executives, American Society for Dermatologic Surgery, American Society for MOHS Surgery, and International Society for Dermatologic Surgery

Disclosure: Nothing to disclose.

Specialty Editor Board

R Stan Taylor, MD  Professor of Dermatology, University of Texas Southwestern Medical School; Director of Skin Surgery and Oncology Clinic, Department of Dermatology, University of Texas Southwestern Medical Center

R Stan Taylor, MD is a member of the following medical societies: American Academy of Dermatology, American College of Mohs Surgery, American Dermatological Association, American Medical Association, American Society for Dermatologic Surgery, Christian Medical & Dental Society, and Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Richard P Vinson, MD  Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association

Disclosure: Nothing to disclose.

Mary Farley, MD  Dermatologic Surgeon/Mohs Surgeon, Anne Arundel Surgery Center

Disclosure: Nothing to disclose.

Glen H Crawford, MD  Assistant Clinical Professor, Department of Dermatology, University of Pennsylvania School of Medicine; Chief, Division of Dermatology, The Pennsylvania Hospital

Glen H Crawford, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Phi Beta Kappa, and Society of USAF Flight Surgeons

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD  Director, Department of Dermatology, Geisinger Medical Center

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

References

  1. Galadari E, Mehregan AH, Lee KC. Malignant transformation of eccrine tumors. J Cutan Pathol. Feb 1987;14(1):15-22. [Medline].

  2. Takata M, Hashimoto K, Mehregan P, et al. Genetic changes in sweat gland carcinomas. J Cutan Pathol. Jan 2000;27(1):30-5. [Medline].

  3. Biernat W, Peraud A, Wozniak L, Ohgaki H. p53 mutations in sweat gland carcinomas. Int J Cancer. May 4 1998;76(3):317-20. [Medline].

  4. Abbate M, Zeitouni NC, Seyler M, Hicks W, Loree T, Cheney RT. Clinical course, risk factors, and treatment of microcystic adnexal carcinoma: a short series report. Dermatol Surg. Oct 2003;29(10):1035-8. [Medline].

  5. Peterson CM, Ratz JL, Sangueza OP. Microcystic adnexal carcinoma: First reported case in an African American man. J Am Acad Dermatol. Aug 2001;45(2):283-5. [Medline].

  6. Gardner ES, Goldberg LH. Neglected microcystic adnexal carcinoma: the second reported case in a black patient. Dermatol Surg. Jul 2001;27(7):678-80. [Medline].

  7. Chauhan A, Ganguly M, Takkar P, Dutta V. Primary mucinous carcinoma of eyelid: a rare clinical entity. Indian J Ophthalmol. Mar-Apr 2009;57(2):150-2. [Medline].

  8. Bannur HB, Mastiholimath RD, Malur PR. Primary mucinous eccrine adenocarcinoma of the scalp: a case report. Acta Cytol. Nov-Dec 2009;53(6):698-700. [Medline].

  9. Chiller K, Passaro D, Scheuller M, Singer M, McCalmont T, Grekin RC. Microcystic adnexal carcinoma: forty-eight cases, their treatment, and their outcome. Arch Dermatol. Nov 2000;136(11):1355-9. [Medline].

  10. Harwood CA, McGregor JM, Swale VJ, et al. High frequency and diversity of cutaneous appendageal tumors in organ transplant recipients. J Am Acad Dermatol. Mar 2003;48(3):401-8. [Medline].

  11. Scholz IM, Hartschuh W. Primary mucinous eccrine carcinoma of the skin - a rare clinical tumor with many differential diagnoses. J Dtsch Dermatol Ges. Oct 13 2009;[Medline].

  12. Wildemore JK, Lee JB, Humphreys TR. Mohs surgery for malignant eccrine neoplasms. Dermatol Surg. Dec 2004;30(12 Pt 2):1574-9. [Medline].

  13. Penneys NS, Zlatkiss I. Immunohistochemical demonstration of ferritin in sweat gland and sweat gland neoplasms. J Cutan Pathol. Feb 1990;17(1):32-6. [Medline].

  14. Yeung KY, Stinson JC. Mucinous (adenocystic) carcinoma of sweat glands with widespread metastasis. Case report with ultrastructural study. Cancer. Jun 1977;39(6):2556-62. [Medline].

  15. Snow S, Madjar DD, Hardy S, et al. Microcystic adnexal carcinoma: report of 13 cases and review of the literature. Dermatol Surg. Apr 2001;27(4):401-8. [Medline].

  16. Lozano Orella JA, Valcayo Penalba A, San Juan CC, et al. Eccrine porocarcinoma. Report of nine cases. Dermatol Surg. Oct 1997;23(10):925-8. [Medline].

  17. Mehregan AH, Hashimoto K, Rahbari H. Eccrine adenocarcinoma. A clinicopathologic study of 35 cases. Arch Dermatol. Feb 1983;119(2):104-14. [Medline].

  18. Lober CW, Larbig GG. Microcystic adnexal carcinoma (sclerosing sweat duct carcinoma). South Med J. Feb 1994;87(2):259-62. [Medline].

  19. Moy RL, Rivkin JE, Lee H, Brooks WS, Zitelli JA. Syringoid eccrine carcinoma. J Am Acad Dermatol. May 1991;24(5 Pt 2):857-60. [Medline].

  20. Duke WH, Sherrod TT, Lupton GP. Aggressive digital papillary adenocarcinoma (aggressive digital papillary adenoma and adenocarcinoma revisited). Am J Surg Pathol. Jun 2000;24(6):775-84. [Medline].

  21. Cabell CE, Helm KF, Sakol PJ, Billingsley EM. Primary mucinous carcinoma in a 54-year-old man. J Am Acad Dermatol. Nov 2003;49(5):941-3. [Medline].

  22. Cooper PH, Adelson GL, Holthaus WH. Primary cutaneous adenoid cystic carcinoma. Arch Dermatol. Jun 1984;120(6):774-7. [Medline].

  23. Goel R, Contos MJ, Wallace ML. Widespread metastatic eccrine porocarcinoma. J Am Acad Dermatol. Nov 2003;49(5 Suppl):S252-4. [Medline].

  24. Harrist TJ, Aretz TH, Mihm MC Jr, Evans GW, Rodriquez FL. Cutaneous malignant mixed tumor. Arch Dermatol. Nov 1981;117(11):719-24. [Medline].

  25. Hashimoto K, Mehregan AH, Kumakiri M. Tumors of Skin Appendages. Boston, Mass: Butterworth; 1987.

  26. Mitsui H, Watanabe T, Jinnin M, Kadono T, Idezuki T, Tamaki K. Mucinous carcinoma of the skin could have either an eccrine or an apocrine origin. Br J Dermatol. Dec 2004;151(6):1285-6. [Medline].

  27. Murphy GF, Elder DE. Non melanocytic tumors of the skin. In: Atlas of Tumor Pathology. 3rd Series. Fascicle 1. Washington DC: Armed Forces Institute of Pathology; 1991.

  28. Wick MR, Swanson PE, Kaye VN, Pittelkow MR. Sweat gland carcinoma ex eccrine spiradenoma. Am J Dermatopathol. Apr 1987;9(2):90-8. [Medline].

  29. Yildirim S, Aköz T, Akan M, Ege GA. De novo malignant eccrine spiradenoma with an interesting and unusual location. Dermatol Surg. Apr 2001;27(4):417-20. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.